News | May 30, 2013

Six-Month Data Reported for WAVE I Study of Renal Denervation Therapy for Hypertension

Kona Surround Sound technology utilizes externally-delivered ultrasound to treat drug-resistant hypertension.

May 30, 2013 — Kona Medical announced three and six month results from the WAVE I study, a first-in-man study evaluating the safety and efficacy of Kona Medical’s Surround Sound Renal Denervation System for the treatment of resistant hypertension.

Unlike other renal denervation methods, which rely on a catheter emitting energy through the wall of the renal artery, Kona’s system delivers ultrasound energy to the nerves from outside the body. This targeted energy “surrounds” the artery and treats the nerves located in the vicinity of the vessel. Data presented from WAVE I demonstrates that patients treated with the Surround Sound Renal Denervation System had no device-related serious adverse events and experienced a 22 mmHg drop in systolic blood pressure and 9 mmHg drop in diastolic blood pressure at three months (N=24). In those patients who had reached 6 months follow-up (N=14) there was a 29 mmHg drop in systolic blood pressure and 9 mmHg drop in diastolic blood pressure.

“The results from this initial study of external ultrasound for renal denervation are very promising,” said Robert Whitbourn, M.D., of St. Vincent’s Hospital in Melbourne, Australia. “Blood pressure reduction in this very severe hypertensive cohort grows over time. We’ve also seen that the ultrasound energy leads to effective denervation without any discernible effect on the renal artery. While more studies are required to confirm these results, external ultrasound appears to have strong potential as an alternative to catheter based energy delivery for patients with hypertension.”

Additional data reported on WAVE I includes:

  • On average, clinical subjects had a baseline blood pressure of 190 mmHg systolic and 100 mmHg diastolic and were taking an average of 4.5 anti-hypertension medications.
  • 11 out of 14 subjects (78 percent) reaching the six-month efficacy endpoint had a clinically significant drop in systolic blood pressure of 10 mmHg or greater.
  • Results from norepinephrine spillover studies indicate strong evidence of sympathetic denervation.
  • There were no adverse findings in the subjects’ renal vasculature based on six-week angiogram (n=9) and 24 week magnetic resonance imaging (MRI) (n=14).


Currently, the clinical sites are enrolling and treating subjects in a follow-on study, WAVE II, which utilizes an optimized treatment protocol that reduces therapy delivery time from approximately 12 minutes per side (in WAVE I) to under three minutes. Kona Medical also has announced plans to initiate the WAVE III study, which will evaluate the safety and efficacy of a fully external (non-invasive) version of its ultrasound-based therapy.

For more information:

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Overlay Init